Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - A review

Clinical and Experimental Gastroenterology

Volumn 8, Issue , 2015, Pages 237-255

  Moré, Margret I ^a   Swidsinski, Alexander ^b  

^a Analyze and Realize GmbH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Colonic bioreactor; Diarrhea; Dysbiosis; Intestinal mucus layer; Microbiota; Mucosa; Probiotic; Saccharomyces boulardii CNCM I 745; SCFA

Indexed keywords

BACTERIAL TOXIN; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID;

ACTINOBACTERIA; ANTIINFLAMMATORY ACTIVITY; BACILLI; BACTERIAL COLONIZATION; BACTEROIDACEAE; BACTEROIDALES; BACTEROIDETES; BIFIDOBACTERIACEAE; BIFIDOBACTERIALES; CLOSTRIDIA; CLOSTRIDIACEAE; CLOSTRIDIALES; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DYSBIOSIS; ENTEROBACTERIACEAE; ENTEROBACTERIALES; FIRMICUTES; GAMMAPROTEOBACTERIA; GROWTH INHIBITION; HUMAN; IMMUNOSTIMULATION; INTESTINE CELL; INTESTINE FLORA; LACHNOSPIRACEAE; LACTOBACILLALES; MICROBIOME; MUCUS; NONHUMAN; PREVOTELLACEAE; PROTEOBACTERIA; REVIEW; RUMINOCOCCACEAE; SACCHAROMYCES BOULARDII; SACCHAROMYCES BOULARDII CNCM I 745; VERRUCOMICROBIA;

EID: 84940035211     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S85574     Document Type: Review

References (146)

1. Zoetendal EG, Vaughan EE, de Vos WM. A microbial world within us. Mol Microbiol. 2006; 59(6): 1639-1650.
2. Pituch A, Walkowiak J, Banaszkiewicz A. Butyric acid in functional constipation. Prz Gastroenterol. 2013; 8(5): 295-298.
3. Kuwahara A. Contributions of colonic short-chain fatty acid receptors in energy homeostasis. Front Endocrinol. 2014; 5: 144.
4. Royall D, Wolever TM, Jeejeebhoy KN. Clinical significance of colonic fermentation. Am J Gastroenterol. 1990; 85(10): 1307-1312.
5. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care. 2012; 15(5): 474-479.
6. Puertollano E, Kolida S, Yaqoob P. Biological significance of short-chain fatty acid metabolism by the intestinal microbiome. Curr Opin Clin Nutr Metab Care. 2014; 17(2): 139-144.
7. Buckman SA, Heise CP. Nutrition considerations surrounding restorative proctocolectomy. Nutr Clin Pract. 2010; 25(3): 250-256.
8. Claus SP, Ellero SL, Berger B, et al. Colonization-induced host-gut microbial metabolic interaction. MBio. 2011; 2(2): e00271-e00310.
9. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003; 361(9356): 512-519.
10. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1): 121-141.
11. Molloy MJ, Bouladoux N, Belkaid Y. Intestinal microbiota: shaping local and systemic immune responses. Semin Immunol. 2012; 24(1): 58-66.
12. Forsythe P, Bienenstock J. Immunomodulation by commensal and probiotic bacteria. Immunol Invest. 2010; 39(4-5): 429-448.
13. Cani PD. Metabolism in 2013: the gut microbiota manages host metabolism. Nat Rev Endocrinol. 2014; 10(2): 74-76.
14. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010; 10(2): 131-144.
15. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010; 12(5): 319-330.
16. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A. 2008; 105(39): 15064-15069.
17. Ouwerkerk JP, de Vos WM, Belzer C. Glycobiome: bacteria and mucus at the epithelial interface. Best Pract Res Clin Gastroenterol. 2013; 27(1): 25-38.
18. Swidsinski A, Loening-Baucke V, Kirsch S, Doerffel Y. Biostructure fonctionnelle du microbiote colique (zone de fermentation centrale, zone de réserve germinale et couche de mucus séparatrice) chez les sujets sains et chez les patients atteints de diarrhée traités par Saccharomyces boulardii [Functional biostructure of colonic microbiota (central fermenting area, germinal stock area and separating mucus layer) in healthy subjects and patients with diarrhea treated with Saccharomyces boulardii]. Gastroenterol Clin Biol. 2010; 34(Suppl 1): S79-S92. French.
19. Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn's disease and ulcerative colitis-an overview. J Physiol Pharmacol. 2009; 60(Suppl 6): 61-71.
20. Strugala V, Dettmar PW, Pearson JP. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. Int J Clin Pract. 2008; 62(5): 762-769.
21. Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care. 2010; 33(10): 2277-2284.
22. Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM, Comelli EM. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr Diabetes. 2014; 4: e121.
23. Stokholm J, Schjorring S, Eskildsen CE, et al. Antibiotic use during pregnancy alters the commensal vaginal microbiota. Clin Microbiol Infect. 2014; 20(7): 629-635.
24. O'Sullivan O, Coakley M, Lakshminarayanan B, et al. Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy. J Antimicrob Chemother. 2013; 68(1): 214-221.
25. Grover M. Role of gut pathogens in development of irritable bowel syndrome. Indian J Med Res. 2014; 139(1): 11-18.
26. Schneider SM, Le Gall P, Girard-Pipau F, et al. Total artificial nutrition is associated with major changes in the fecal flora. Eur J Nutr. 2000; 39(6): 248-255.
27. Schneider SM. Nutrition entérale et microbiote [Microbiota and enteral nutrition]. Gastroenterol Clin Biol. 2010; 34(Suppl 1): S57-S61. French.
28. O'Keefe SJ, Ou J, Delany JP, et al. Effect of fiber supplementation on the microbiota in critically ill patients. World J Gastrointest Pathophysiol. 2011; 2(6): 138-145.
29. Nakao M, Ogura Y, Satake S, et al. Usefulness of soluble dietary fiber for the treatment of diarrhea during enteral nutrition in elderly patients. Nutrition. 2002; 18(1): 35-39.
30. Chey WD, Cash BD. Irritable bowel syndrome: update on colonic neuromuscular dysfunction and treatment. Curr Gastroenterol Rep. 2006; 8(4): 273-281.
31. Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol. 2014; 20(10): 2482-2491.
32. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011; 11: 7.
33. Thomas LV, Ockhuizen T, Suzuki K. Exploring the influence of the gut microbiota and probiotics on health: a symposium report. Br J Nutr. 2014; 112(Suppl 1): S1-S18.
34. Surawicz CM. Le microbiote dans les diarrhées infectieuses [The microbiota and infectious diarrhea]. Gastroenterol Clin Biol. 2010; 34(Suppl 1): S29-S36. French.
35. Kolling G, Wu M, Guerrant RL. Enteric pathogens through life stages. Front Cell Infect Microbiol. 2012; 2: 114.
36. Ma C, Wu X, Nawaz M, et al. Molecular characterization of fecal microbiota in patients with viral diarrhea. Curr Microbiol. 2011; 63(3): 259-266.
37. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007; 26(4): 535-544.
38. Barbara G, Stanghellini V, Berti-Ceroni C, et al. Role of antibiotic therapy on long-term germ excretion in faeces and digestive symptoms after Salmonella infection. Aliment Pharmacol Ther. 2000; 14(9): 1127-1131.
39. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005; 18(2): 247-263.
40. Wang L, Conlon MA, Christophersen CT, Sorich MJ, Angley MT. Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders. Biomark Med. 2014; 8(3): 331-344.
41. Kang DW, Park JG, Ilhan ZE, et al. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS One. 2013; 8(7): e68322.
42. Swidsinski A, Loening-Baucke V, Krüger M, Kirsch S. Central nervous system and the colonic bioreactor: analysis of colonic microbiota in patients with stroke unravels unknown mechanisms of the host defense after brain injury. Intest Res. 2012; 10(4): 332-342.
43. Kimura I, Ozawa K, Inoue D, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013; 4: 1829.
44. Moayyedi P. The epidemiology of obesity and gastrointestinal and other diseases: an overview. Dig Dis Sci. 2008; 53(9): 2293-2299.
45. Kanauchi O, Matsumoto Y, Matsumura M, Fukuoka M, Bamba T. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr Pharm Des. 2005; 11(8): 1047-1053.
46. Forster C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol. 2008; 130(1): 55-70.
47. Thanabalasuriar A, Koutsouris A, Weflen A, Mimee M, Hecht G, Gruenheid S. The bacterial virulence factor NleA is required for the disruption of intestinal tight junctions by enteropathogenic Escherichia coli. Cell Microbiol. 2010; 12(1): 31-41.
48. Shen L. Tight junctions on the move: molecular mechanisms for epithelial barrier regulation. Ann N Y Acad Sci. 2012; 1258: 9-18.
49. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology. 2008; 135(2): 568-579.
50. Swidsinski A, Ung V, Sydora BC, et al. Bacterial overgrowth and inflammation of small intestine after carboxymethylcellulose ingestion in genetically susceptible mice. Inflamm Bowel Dis. 2009; 15(3): 359-364.
51. Zhu L, Liu W, Alkhouri R, et al. Structural changes in the gut microbiome of constipated patients. Physiol Genomics. 2014; 46(18): 679-686.
52. Chassard C, Dapoigny M, Scott KP, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. 2012; 35(7): 828-838.
53. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics-Saccharomyces boulardii. Aliment Pharmacol Ther. 2007; 26(6): 767-778.
54. Liti G, Carter DM, Moses AM, et al. Population genomics of domestic and wild yeasts. Nature. 2009; 458(7236): 337-341.
55. MacKenzie DA, Defernez M, Dunn WB, et al. Relatedness of medically important strains of Saccharomyces cerevisiae as revealed by phylogenetics and metabolomics. Yeast. 2008; 25(7): 501-512.
56. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos. 1989; 10(4): 353-364.
57. Elmer GW, McFarland LV, Surawicz CM, Danko L, Greenberg RN. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther. 1999; 13(12): 1663-1668.
58. Barc MC, Charrin-Sarnel C, Rochet V, et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: influence of Saccharomyces boulardii. Anaerobe. 2008; 14(4): 229-233.
59. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005; 40(11): 1625-1634.
60. Llopis S, Querol A, Heyken A, et al. Transcriptomics in human blood incubation reveals the importance of oxidative stress response in Saccharomyces cerevisiae clinical strains. BMC Genomics. 2012; 13: 419.
61. Perez-Torrado R, Llopis S, Perrone B, Gomez-Pastor R, Hube B, Querol A. comparative genomic analysis reveals a critical role of de novo nucleotide biosynthesis for Saccharomyces cerevisiae virulence. PLoS One. 2015; 10(3): e0122382.
62. Edwards-Ingram L, Gitsham P, Burton N, et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol. 2007; 73(8): 2458-2467.
63. Graff S, Chaumeil JC, Boy P, Lai-Kuen R, Charrueau C. Influence of pH conditions on the viability of Saccharomyces boulardii yeast. J Gen Appl Microbiol. 2008; 54(4): 221-227.
64. Czerucka D, Nano JL, Bernasconi P, Rampal P. Effect of Saccharomyces boulardii on cholera toxin-induced camp level in rat epithelial intestinal cell lines. Gastroenterol Clin Biol. 1989; 13: 383-387.
65. Elmer GW, Corthier G. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. Can J Microbiol. 1991; 37(4): 315-317.
66. Schwenzer V. Saccharomyces boulardii. Deutsche Apotheker Zeitung. 1998; 138: 75-77.
67. Dinleyici EC, Kara A, Ozen M, Vandenplas Y. Saccharomyces boulardii CNCM I-745 in different clinical conditions. Expert Opin Biol Ther. 2014: 1-17.
68. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010; 16(18): 2202-2222.
69. Zanello G, Meurens F, Berri M, Salmon H. Saccharomyces boulardii effects on gastrointestinal diseases. Curr Issues Mol Biol. 2009; 11(1): 47-58.
70. McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014; 4(8): e005047.
71. Micklefield G. Saccharomyces coulardii bei Antibiotika-assoziierter Diarrhöe [Saccharomyces boulardii with antibiotic-associated diarrhea]. MMW-Fortschritte der Medizin Originalien 2014; 156(1 Suppl): 18-22. German.
72. Na X, Kelly C. Probiotics in Clostridium difficile infection. J Clin Gastroenterol. 2011; 45(Suppl): S154-S158.
73. Tung JM, Dolovich LR, Lee CH. Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Can J Gastroenterol. 2009; 23(12): 817-821.
74. Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prophylaxe der reisediarrhoe mit Saccharomyces boulardii [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr Med. 1993; 111(9): 152-156. German.
75. Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014; 134(1): e176-e191.
76. Guandalini S. Probiotics for children with diarrhea: an update. J Clin Gastroenterol. 2008; 42(Suppl 2): S53-S57.
77. Whelan K. Enteral-tube-feeding diarrhoea: manipulating the colonic microbiota with probiotics and prebiotics. Proc Nutr Soc. 2007; 66(3): 299-306.
78. Tempe JD, Steidel AL, Blehaut H, Hasselmann M, Lutun P, Maurier F. Prévention per Saccharomyces boulardii des diarrhées de l'alimentation entérale à débit continu [Prevention of diarrhea administering Saccharomyces boulardii during continuous enteral feeding]. Sem Hop. 1983; 59(18): 1409-1412. French.
79. Schlotterer M, Bernasconi P, Lebreton F, et al. Intérêt de Saccharomyces boulardii dans la tolerance digestive de la nutrition entérale à debit continu chez le brulé. [Use of Saccharomyces boulardii for the improvement of the tolerance of continuous enteral feeding in burn patients]. Nutr Clin Metabol. 1987; 1: 31-34. French.
80. Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med. 1997; 23(5): 517-523.
81. Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol. 2012; 5(2): 111-125.
82. Barreto-Bergter E, Figueiredo RT. Fungal glycans and the innate immune recognition. Front Cell Infect Microbiol. 2014; 4: 145.
83. Samuelsen AB, Schrezenmeir J, Knutsen SH. Effects of orally administered yeast-derived β-glucans: a review. Mol Nutr Food Res. 2014; 58(1): 183-193.
84. Vannucci L, Krizan J, Sima P, et al. Immunostimulatory properties and antitumor activities of glucans (Review). Int J Oncol. 2013; 43(2): 357-364.
85. Goodridge HS, Reyes CN, Becker CA, et al. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature. 2011; 472(7344): 471-475.
86. Pothoulakis C. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther. 2009; 30(8): 826-833.
87. Mumy KL, Chen X, Kelly CP, McCormick BA. Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol. 2008; 294(3): G599-G609.
88. Pontier-Bres R, Munro P, Boyer L, et al. Saccharomyces boulardii modifies Salmonella typhimurium traffic and host immune responses along the intestinal tract. PLoS One. 2014; 9(8): e103069.
89. Rajput IR, Li LY, Xin X, et al. Effect of Saccharomyces boulardii and Bacillus subtilis B10 on intestinal ultrastructure modulation and mucosal immunity development mechanism in broiler chickens. Poult Sci. 2013; 92(4): 956-965.
90. Martins FS, Vieira AT, Elian SD, et al. Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. Microbes Infect. 2013; 15(4): 270-279.
91. Girard P, Pansart Y, Coppe MC, Gillardin JM. Saccharomyces boulardii inhibits water and electrolytes changes induced by castor oil in the rat colon. Dig Dis Sci. 2005; 50(11): 2183-2190.
92. Schroeder B, Winckler C, Failing K, Breves G. Studies on the time course of the effects of the probiotic yeast Saccharomyces boulardii on electrolyte transport in pig jejunum. Dig Dis Sci. 2004; 49(7-8): 1311-1317.
93. Czerucka D, Rampal P. Effect of Saccharomyces boulardii on cAMP-and Ca2+-dependent Cl-secretion in T84 cells. Dig Dis Sci. 1999; 44(11): 2359-2368.
94. Buccigrossi V, Laudiero G, Russo C, et al. Chloride secretion induced by rotavirus is oxidative stress-dependent and inhibited by Saccharomyces boulardii in human enterocytes. PLoS One. 2014; 9(6): e99830.
95. Schneider SM, Girard-Pipau F, Filippi J, et al. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol. 2005; 11(39): 6165-6169.
96. Breves G, Faul K, Schroder B, Holst H, Caspary WF, Stein J. Application of the colon-simulation technique for studying the effects of Saccharomyces boulardii on basic parameters of porcine cecal microbial metabolism disturbed by clindamycin. Digestion. 2000; 61(3): 193-200.
97. Oeztuerk H, Schroeder B, Beyerbach M, Breves G. Influence of living and autoclaved yeasts of Saccharomyces boulardii on in vitro ruminal microbial metabolism. J Dairy Sci. 2005; 88(7): 2594-2600.
98. Jahn HU, Ullrich R, Schneider T, et al. Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion. 1996; 57(2): 95-104.
99. Buts JP, De Keyser N, De Raedemaeker L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res. 1994; 36(4): 522-527.
100. Buts JP, De Keyser N, Marandi S, et al. Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut. 1999; 45(1): 89-96.
101. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 1996; 64(12): 5225-5232.
102. Brandao RL, Castro IM, Bambirra EA, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol. 1998; 64(2): 564-568.
103. Buts JP, Dekeyser N, Stilmant C, Delem E, Smets F, Sokal E. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res. 2006; 60(1): 24-29.
104. Tiago FC, Martins FS, Souza EL, et al. Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. J Med Microbiol. 2012; 61(Pt 9): 1194-1207.
105. Martins FS, Dalmasso G, Arantes RM, et al. Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection. PLoS One. 2010; 5(1): e8925.
106. Gedek BR. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses. 1999; 42(4): 261-264.
107. Zbinden R, Gönczi E-E, Altwegg M. Inhibition of Saccharomyces boulardii (nom. inval.) on cell invasion of Salmonella typhimurium and Yersinia enterocolitica. Microb Ecol Health Dis. 2011; 11(3). ISSN 1651-2235.
108. Ducluzeau R, Bensaada M. [Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice]. Ann Microbiol. 1982; 133(3): 491-501. French.
109. Kamada N, Chen GY, Inohara N, Nunez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013; 14(7): 685-690.
110. Geurts L, Lazarevic V, Derrien M, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol. 2011; 2: 149.
111. Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio. 2014; 5(3): e01011-e01014.
112. Akil I, Yilmaz O, Kurutepe S, Degerli K, Kavukcu S. Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora. Pediatr Nephrol. 2006; 21(6): 807-810.
113. De Preter V, Vanhoutte T, Huys G, Swings J, Rutgeerts P, Verbeke K. Effect of lactulose and Saccharomyces boulardii administration on the colonic urea-nitrogen metabolism and the bifidobacteria concentration in healthy human subjects. Aliment Pharmacol Ther. 2006; 23(7): 963-974.
114. Girard-Pipau F, Pompei A, Schneider S, et al. Intestinal microflora, short chain and cellular fatty acids, influence of a probiotic Saccharomyces boulardii. Microb Ecolo Health Dis. 2002; 14: 220-227.
115. Vanhoutte T, De Preter V, De Brandt E, Verbeke K, Swings J, Huys G. Molecular monitoring of the fecal microbiota of healthy human subjects during administration of lactulose and Saccharomyces boulardii. Appl Environ Microbiol. 2006; 72(9): 5990-5997.
116. Kelly C. Antibiotic-induced dysbiosis and corrective impact of S. boulardii in healthy volunteers (Abstract-JFHOD conference). United Eur Gastroenterol J. 2014; 2(Suppl 1).
117. Osowska S, Swidsinski A, Kulik Z, Lawinski M, Pertkiewicz M. Impact of saccharomyces boulardii on colonic microbiota and plasma lactate in short bowel syndrome patients on long term parenteral nutrition. Dig Dis Week. 2013; 144(5): s895.
118. Swidsinski A. Antibiotic-induced dysbiosis and corrective impact of S. boulardii-evaluation by structure functional FISH analysis in patients with a Gardnerella vaginalis infection. Abstract-JFHOD conference. 2014.
119. Swidsinski A, Loening-Baucke V, Swidsinski S. Saccharomyces boulardii prevents the antibiotic induced changes in colonic microbiota. Gastroenterology. 2013; 144(5 Suppl 1): S-824.
120. Staib L, Fuchs TM. From food to cell: nutrient exploitation strategies of enteropathogens. Microbiology. 2014; 160(Pt 6): 1020-1039.
121. Chen SJ, Liu XW, Liu JP, Yang XY, Lu FG. Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. World J Gastroenterol. 2014; 20(28): 9468-9475.
122. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007; 20(4): 593-621.
123. Zitomersky NL, Atkinson BJ, Franklin SW, et al. Characterization of adherent bacteroidales from intestinal biopsies of children and young adults with inflammatory bowel disease. PLoS One. 2013; 8(6): e63686.
124. Manz W, Amann R, Ludwig W, Vancanneyt M, Schleifer KH. Application of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum cytophaga-flavobacter-bacteroides in the natural environment. Microbiology. 1996; 142(Pt 5): 1097-1106.
125. Yutin N, Galperin MY. A genomic update on clostridial phylogeny: Gram-negative spore formers and other misplaced clostridia. Environ Microbiol. 2013; 15(10): 2631-2641.
126. Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio. 2014; 5(2): e00889.
127. NCBI Taxomomy Browser. Taxomomy Browser. Available from: http://www. ncbi. nlm. nih. gov/Taxonomy/Browser/wwwtax. cgi. Accessed July 2, 2015.
128. Kabeerdoss J, Sankaran V, Pugazhendhi S, Ramakrishna BS. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol. 2013; 13: 20.
129. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105(43): 16731-16736.
130. Qiu X, Zhang M, Yang X, Hong N, Yu C. Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohns Colitis. 2013; 7(11): e558-e568.
131. Kumari A, Catanzaro R, Marotta F. Clinical importance of lactic acid bacteria: a short review. Acta Biomed. 2011; 82(3): 177-180.
132. Turpin W, Humblot C, Thomas M, Guyot JP. Lactobacilli as multifaceted probiotics with poorly disclosed molecular mechanisms. Int J Food Microbiol. 2010; 143(3): 87-102.
133. Iqbal MZ, Qadir MI, Hussain T, Janbaz KH, Khan YH, Ahmad B. Review: probiotics and their beneficial effects against various diseases. Pak J Pharm Sci. 2014; 27(2): 405-415.
134. Lay C, Rigottier-Gois L, Holmstrom K, et al. Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol. 2005; 71(7): 4153-4155.
135. Thiennimitr P, Winter SE, Winter MG, et al. Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota. Proc Natl Acad Sci U S A. 2011; 108(42): 17480-17485.
136. Philippe-Taine G, Coroler L, Levy R, Gillardin J. Dose-dependent preventive effect of Saccharomyces boulardii on clindamycin-induced alterations in intestinal aerobic flora of the hamster. Microbial Ecol Health Dis. 2003; 15: 126-130.
137. Collignon A, Sandre C, Barc MC. Saccharomyces boulardii module les propriétés des cellules dendritiques et le déséquilibre du microbiote intestinal après un traitement antibiotique [Saccharomyces boulardii modulates dendritic cell properties and intestinal microbiota disruption after antibiotic treatment]. Gastroenterol Clin Biol. 2010; 34(Suppl 1): S71-S78. French.
138. Dubourg G, Lagier JC, Armougom F, et al. High-level colonisation of the human gut by Verrucomicrobia following broad-spectrum antibiotic treatment. Int J Antimicrob Agents. 2013; 41(2): 149-155.
139. Bradlow HL. Obesity and the gut microbiome: pathophysiological aspects. Hormone Mol Biol Clin Invest. 2014; 17(1): 53-61.
140. Scanlan PD, Shanahan F, Marchesi JR. Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol. 2008; 8: 79.
141. Loy A, Maixner F, Wagner M, Horn M. probeBase-an online resource for rRNA-targeted oligonucleotide probes: new features 2007. Nucleic Acids Res. 2007; 35(Database issue): D800-D804.
142. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122): 1027-1031.
143. Sghir A, Gramet G, Suau A, Rochet V, Pochart P, Dore J. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl Environ Microbiol. 2000; 66(5): 2263-2266.
144. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol. 2004; 70(12): 7220-7228.
145. Franks AH, Harmsen HJ, Raangs GC, Jansen GJ, Schut F, Welling GW. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol. 1998; 64(9): 3336-3345.
146. Harmsen HJ, Wildeboer-Veloo AC, Grijpstra J, Knol J, Degener JE, Welling GW. Development of 16S rRNA-based probes for the Coriobacterium group and the Atopobium cluster and their application for enumeration of Coriobacteriaceae in human feces from volunteers of different age groups. Appl Environ Microbiol. 2000; 66(10): 4523-4527.